BLPH - ベレロフォン・セラピュ―ティクス (Bellerophon Therapeutics Inc.) ベレロフォン・セラピュ―ティクス

 BLPHのチャート


 BLPHの企業情報

symbol BLPH
会社名 Bellerophon Therapeutics Inc (ベレロフォン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Bellerophon Therapeutics Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system INOpulse with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs which minimizes the amount of drug required for treatment. The Company''s second program BCM is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI) which is a type of severe heart attack. The Company''s BCM is in PRESERVATION I clinical trial.   ベレロフォン・セラピュ―ティクスは、米国のバイオ医薬品会社。心肺や心臓疾患の治療における医療ニ―ズに対応する薬と装置を中心に製品開発を行う。最初のプログラムであるINOpulseは、拍動一酸化窒素送達デバイスに基づいて開発され、肺動脈高血圧症の治療のための製品と、慢性閉塞性肺疾患に関連する肺高血圧症の治療用の製品を提供する。   Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system.
本社所在地 184 Liberty Corner Road Suite 302 Warren NJ 07059 USA
代表者氏名 Jonathan M. Peacock ジョナサン・M・ピーコック
代表者役職名 Chairman of the Board President 取締役会長会長
電話番号 +1 908-574-4770
設立年月日 41548
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 20人
url www.bellerophon.com
nasdaq_url https://www.nasdaq.com/symbol/blph
adr_tso
EBITDA EBITDA(百万ドル) -29.49600
終値(lastsale) 1.23
時価総額(marketcap) 71092323.51
時価総額 時価総額(百万ドル) 67.62441
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 41.72541
当期純利益 当期純利益(百万ドル) -39.12000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Bellerophon Therapeutics Inc revenues was not reported. Net loss decreased 68% to $7.4M. Lower net loss reflects Change in fair value of common stock war increase from $12M (expense) to $3.4M (income) Interest and other income increase from $53K to $190K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.72 to -$0.13.

 BLPHのテクニカル分析


 BLPHのニュース

   This Healthcare Stock Jumps Around 188%, Here''s 83 Biggest Movers From Yesterday  2022/06/28 08:23:47 Benzinga
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM ) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. Acutus Medical, Inc. (NASDAQ: AFIB ) climbed 87.6% to close at $1.01 after the company announced the commercial launch of its left-heart access products. Epizyme, Inc. (NASDAQ: EPZM ) jumped 55.1% to close at $1.48. Ipsen SA (OTC: IPSEY ) agreed to acquire Epizyme at $1.45 per share for approximately $247 million, plus one contingent value right (CVR) per share. Axsome Therapeutics, Inc. (NASDAQ: AXSM ) shares surged 51.4% to settle at $37.03 after the company received proposed labeling from the U.S. Food and Drug Administration for its treatment of major depressive disorder. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN ) surged 48.8% to close at $2.50 after the company reported results from a stage III ALS Biomarker study evaluating PrimeC. Preliminary results showed levels of disease-related biomarkers in people with ALS were steady, in contrast to a statistically significant decline portrayed in biomarkers when PrimeC was administered.
   Bellerophon Therapeutics GAAP EPS of -$0.59 misses by $0.04  2022/05/11 12:41:27 Seeking Alpha
Bellerophon Therapeutics press release (BLPH): Q1 GAAP EPS of -$0.59 misses by $0.04.As of March 31, 2022, the Company had cash and cash equivalents of $20.0 million, compared to…
   Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results  2022/05/11 12:30:00 GlobeNewswire
WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022.
   Bellerophon Therapeutics GAAP EPS of -$1.87 (NASDAQ:BLPH)  2022/03/31 20:45:38 Seeking Alpha
Bellerophon Therapeutics press release (BLPH): FY GAAP EPS of -$1.87.As of December 31, 2021, the company had cash and cash equivalents of $24.7 million, compared to cash and…
   Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results  2022/03/31 20:01:00 GlobeNewswire
WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2021.
   Telemetry Investments L.L.C. Raises Holdings in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)  2021/10/23 14:23:11 Transcript Daily
Telemetry Investments L.L.C. grew its position in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) by 48.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 90,920 shares of the biotechnology companys stock after buying an additional 29,878 shares during the period. Telemetry Investments L.L.C. owned []
   Bellerophon Therapeutics (BLPH ) Investor Presentation - Slideshow  2021/09/17 19:57:34 Seeking Alpha
   Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference  2021/09/07 12:30:00 Intrado Digital Media
WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23 rd Annual Global Investment Conference, being held September 13-15, 2021.
   Bellerophon Therapeutics EPS beats by $0.25  2021/08/05 13:11:45 Seeking Alpha
   Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results  2021/08/05 12:30:00 Intrado Digital Media
WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2021.
   Bellerophon Therapeutics (BLPH ) Investor Presentation - Slideshow  2021/09/17 19:57:34 Seeking Alpha
   Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference  2021/09/07 12:30:00 Intrado Digital Media
WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23 rd Annual Global Investment Conference, being held September 13-15, 2021.
   Bellerophon Therapeutics EPS beats by $0.25  2021/08/05 13:11:45 Seeking Alpha
   Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results  2021/08/05 12:30:00 Intrado Digital Media
WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2021.
   2 Falling Knives to Catch  2021/07/06 16:46:30 GuruFocus
Athenex and Bellerophon Therapeutics have declined more than 59% over the past 52 weeks Related Stocks: ATNX , BLPH ,

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ベレロフォン・セラピュ―ティクス BLPH Bellerophon Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)